3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma
7
Leukemia
6
Neoplasms, Plasma Cell
5
Infections
5
Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, Non-Hodgkin
3
Leukemia, Biphenotypic, Acute
2
Waldenstrom Macroglobulinemia
1
Thrombocythemia, Essential
1
Sezary Syndrome
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Prolymphocytic
1
Interventions
Cyclophosphamide
40
fludarabine
36
fludarabine phosphate
28
Tacrolimus
20
Whole-Body Irradiation
18
Mycophenolic Acid
18
Busulfan
18
Melphalan
16
thymoglobulin
14
Rituximab
13
Antilymphocyte Serum
12
venetoclax
11
Thiotepa
10
Nivolumab
9
Methotrexate
9
Granulocyte Colony-Stimulating Factor
9
Stem Cell Transplantation
8
Peripheral Blood Stem Cell Transplantation
8
Cyclosporine
8
trametinib
7
Sirolimus
7
Cytarabine
7
Azacitidine
7
AP 1903 reagent
7
Filgrastim
6
Dexamethasone
6
aldesleukin
5
Mesna
5
Ipilimumab
5
Interleukin-2
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
Trimethoprim, Sulfamethoxazole Drug Combination
×
Lymphoid
×
Clear all
NCT05678621
2024-04-19
RATIONALISE
Monash University
Phase 2/3
Recruiting
300 enrolled